Macrophage-derived apolipoprotein (apo) E and multimers of a synthetic apo E-peptide display monokine-like functions by inhibiting mitogen-or antigen-driven lymphocyte proliferation. This study demonstrated how the target lymphocyte itself can modulate macrophage apo E production. The lymphokine interferon-'y (IFN) dramatically inhibited the accumulation of apo E in the supernatant of human monocytic THP-1 cells when present during phorbol myristate acetate-induced differentiation. A similar effect was observed when IFN was added to differentiated THP-1 cells. Treatment with IFN did not change the steady-state levels of apo E mRNA. Furthermore, in the presence of IFN no increased degradation or increased uptake of extracellular apo E was detected. Pulse-chase experiments indicated that IFN reduced the accumulation of extracellular apo E and increased the degradation of intracellular apo E. The inhibitory effect of IFN on apo E production also was observed in human monocyte-derived macrophages. Thus, our data demonstrated that IFN inhibited macrophage apo E production by posttranslational mechanisms. This represents a previously uncharacterized immunoregulatory interaction and lends further support to a relationship between lipid metabolism and the immune system. (J. Clin.
Introduction
Apolipoprotein (apo) E is a major constituent of several subclasses of plasma lipoproteins and displays an important function in lipid metabolism as a targeting protein in receptor-mediated uptake of lipoproteins ( 1 ) . However, unlike most apolipoproteins, which are produced mainly in the liver and the small intestine, apo E is synthesized also by numerous peripheral tissues including macrophages (2) (3) (4) .
The regulation of apo E expression in macrophages is complex, and is dependent on the differentiation state of the cell (5) . Cultured human monocytic THP-1 cells increase apo E expression during differentiation into macrophages, and this expression is regulated by both transcriptional and posttranscriptional mechanisms (6, 7) . In mouse peritoneal macro-phages, a variety of activating agents including bacterial endotoxin modulate apo E expression (8, 9) . We have shown that human monocyte-derived macrophages cultured in the presence ofactivated platelets or the releasates ofactivated platelets manifest a dramatic increase in their secretion ofapo E ( 10). In mouse macrophages and differentiated THP-I cells, cholesterol loading increases apo E gene transcription resulting in increased levels of both apo E mRNA and apo E protein (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Furthermore, a recent report indicates that HDL-induced apo E production in the mouse macrophage cell line, J774, is regulated by posttranslational mechanisms ( 14) .
It has been suggested that apo E produced by macrophages and other extrahepatic tissues plays a role in the movement of cholesterol from peripheral tissues to the liver and may serve as a targeting molecule for local redistribution of cholesterol within tissues undergoing remodeling ( 1). Furthermore, our laboratory has demonstrated that apo E isolated from human monocyte-derived macrophage culture supernatants or synovial fluids also has immunoregulatory monokine-like functions ( 15) . We have shown that macrophage-derived apo E is a potent inhibitor ofmitogen-or antigen-driven lymphocyte proliferation ( 16) and apo E isolated from synovial fluids inhibits neutrophil functions ( 17) . Apo E is the biologically active component of the plasma immunoregulatory lipoprotein, LDL-In ( 18) . In addition, we have shown recently that multimers of a synthetic peptide representing amino acid residues 141-155 of the human apo E molecule can mimic its inhibitory effect on lymphocyte proliferation ( 19) .
The present study was designed to identify mechanisms by which the target lymphocyte itself could modulate the expression of macrophage apo E. IFN is a potent lymphokine that is secreted mainly by activated T lymphocytes and has numerous effects on cells of monocytic lineage (20, 21 ) . A preliminary report noted that IFN reduces apo E production in mouse macrophages (22) . For a detailed analysis of the effects of IFN on apo E expression, we have used human THP-1 monocytic cells (23) , a widely used model for studying monocyte / macrophage function (24, 25) . We and others have shown that THP-1 cells take on macrophage-like characteristics when stimulated with phorbol ester (25, 26) . In the present study we demonstrated that IFN dramatically inhibited the production of apo E in THP-1 macrophage-like cells by posttranslational mechanisms. In addition, we identified a similar inhibitory effect of IFN on apo E production in human monocyte-derived macrophages.
Methods
Cell culture. THP-l cells (American Type Culture Collection, Rock- ville, MD) were maintained in suspension at a density of 2.0 x 105 to 1.0 x 106/ml in RPMI-1640 (low endotoxin) containing 7% fetal calf serum, 10 mM Hepes, 1 mM glutamine, 100 U/ml penicillin, 100 ditions as described earlier (26) by washing the cells and replacing the 7% fetal calf serum with 1% Nutridoma-HU (Boehringer Mannheim Biochemicals, Indianapolis, IN). Unless otherwise stated, cells were plated at a density of 5 X 105 cells in 1 ml per well in 24-well tissue culture dishes. PBMC were isolated using Ficoll-Hypague as described earlier (26) . Monocytes were isolated from PBMC using Sepracell-MN (Sepratech Corp., Oklahoma City, OK) and by an additional adherence step on fibronectin-coated tissue culture plates (Collaborative Research Inc., Bedford, MA). The purity of the monocyte preparation was > 95% as determined by nonspecific esterase staining (10) . The monocytes were cultured under low-endotoxin conditions at a density of 1 X 106 cells in 1 ml per well in 24-well tissue culture dishes as described (26, 27) . PMA (Sigma Chemical Co., St. Louis, MO) was used at a concentration of l0-7 M for THP-l cells and 10-8 M for isolated monocytes throughout the study. Recombinant human interferon-y (2.5 X I07' U/mg) was obtained from Genzyme Corp., Cam- bridge, MA. Viability of cells was monitored by trypan blue exclusion, and cellular DNA and protein were determined as described previously (26) .
Competitive apo E immunoassay. Apo E in the supernatant was measured with a solid-phase radioimmunoassay performed as described previously (10) using '25I-labeled apo E purified from human plasma VLDL and a human apo E-specific monoclonal antibody, l E.
PAGE and Western blot analysis. Electrophoresis was performed with 3-20% gradient polyacrylamide slab gels (0.1% SDS) and carried out at 12 mA for 20 h at room temperature as previously described ( 10) . For protein staining, the gel was stained with Coomassie Blue and destained with methanol-acetic acid. The proteins were transferred to a nitrocellulose membrane by electrophoresis as described earlier (10) . After transfer, the nitrocellulose membranes were incubated with ascites fluid containing an apo E-specific monoclonal antibody, IE, washed, and incubated with polyclonal goat anti-mouse IgG antibody. Antibody binding to apo E was visualized on X-ray film using the Immune-Lite chemiluminescent assay kit (Bio Rad Laboratories, Richmond, CA).
RNA isolation, Northern blotting, and hybridization. Cells were seeded at a density of2-3 X 106 cells in 4 ml per well in six-well culture dishes. Total cellular RNA was purified by the acid guanidinium thiocyanate-phenol-chloroform extraction (28) . Northern blotting and hybridization were performed as described earlier (24) . Briefly, RNA was subjected to denaturing electrophoresis in 1.2% agarose-formaldehyde gels (29) and was transferred to GeneScreen (Du Pont-New England Nuclear, Boston, MA). An apo E cDNA fragment was obtained from American Type Culture Collection ( 30) and used to generate a 29 l-bp cDNA probe. This apo E cDNA probe was radiolabeled with [a-32P]dATP (7, 000 Ci/mmol; Amersham Corp., Arlington Heights, IL) by the random primer method (Boehringer-Mannheim Biochemicals, Indianapolis, IN) to give a specific activity of > 108 cpm/ Mg. Prehybridization, hybridization (1 X 106 cpm/ml), and posthybridization washes were performed using 5% SDS exactly as described (31 ) . Blots were analyzed by autoradiography and apo E mRNA levels were quantitated by scanning densitometry using an Ultroscan XL laser densitometer (LKB Produkter, Bromma, Sweden). The level ofthe "housekeeping" CHO-B mRNA was used as a control to normalize the amounts of RNA loaded (24) .
[35S]Methionine labeling ofcells. Cells were incubated in the presence of PMA±IFN for different time intervals. The cells were washed between media changes with methionine-free RPMI-1640 before the pulse period and with regular RPMI-1640 before the chase period. For labeling, cells were incubated with 0.25 ml of methionine-free RPMI-1640 medium containing 100 jCi/ml (THP-1 cells) or 200 MCi/ml (monocyte-derived macrophages) of L-[35S]methionine (1100 Ci/ mmol, Du Pont-New England Nuclear, Boston, MA) and 1 MM of unlabeled L-methionine. When appropriate, the pulse was followed by 0.25 ml of chase medium (regular RPMI-1640, containing 500 MM of unlabeled methionine) for the time periods indicated. Both the pulse and the chase medium contained 1% Nutridoma, IOmM Hepes, 1 mM glutamine, 100 U/ml penicillin, 100 ,g/ml streptomycin, 1 mM sodium pyruvate, and 5 X l0-5 M (l-mercaptoethanol.
At the end of the incubation period, 100 kallikrein-inactivating units aprotinin and 0.1 mM PMSF were added to the wells to give a total volume of 0.275 ml and the medium was removed to prechilled microcentrifuge tubes. The samples were spun for 5 min at 10,000 gin a microcentrifuge to remove any floating cells. The supernatants were then precleared by adding 0.05 ml of a 10% suspension of protein A Sepharose CL-4B (Pharmacia-LKB, Piscataway, NJ) and rotating the tubes at 4VC for 45 min. The samples were spun at 10,000 gfor 2 min to remove the protein A Sepharose beads and frozen at -20'C.
The cells were lysed with 0.275 ml of lysis buffer containing 0.5% Nonidet P-40, 150 mM NaCl, 10 mM Tris-HCl (pH 7.5), 1.5 mM MgCl2, 100 kallikrein-inactivating units aprotinin, and 0.1 mM PMSF. After vigorous scraping, the cell lysate was pipetted into prechilled microcentrifuge tubes and spun for 10 min at 10,000 g to remove any cell debris and also precleared with 0.05 ml of protein A Sepharose CL-4B beads as described above.
Immunoprecipitation of Apo E. Immunoprecipitation was performed as described earlier (4, 14) with several modifications. To reduce nonspecific binding, protein A Sepharose CL-4B (10% suspension in immunoprecipitation buffer, see below, 0.2% BSA) was pretreated with unlabeled cell extract from dividing THP-I cells immediately before the experiment (rotator, 4°C, 45 min). 35S-incorporation into protein of cell lysate and culture supernatant was determined by TCA precipitation ( 10%) of 0.01 ml of sample. Equal amounts of TCA-precipitable counts of cell lysate or supernatant were incubated on a rotator at 4°C for 12 h with 5 Mg of apo E-specific monoclonal antibody, 0.5 ml of immunoprecipitation buffer (0.5% Nonidet P-40, 0.5% deoxycholic acid, 150 mM NaCl, 5 mM EDTA, 50 mM Tris [pH 7.4], 0.1% SDS, 0.02% sodium azide), and 0.03 ml of protein A Sepharose CL-4B beads. Nonspecific background was reduced as described (32) by layering the entire reaction mixture over a 1 M sucrose cushion, solubilizing the samples in 1% SDS and repeating the immunoprecipitation reaction.
After immunoprecipitation, the beads were washed five times and analyzed by gel electrophoresis and scintillation counting. For gel analysis, pellets were resuspended in Laemmli's sample buffer (lX: 10% glycerol, 5% fl-mercaptoethanol, 3% SDS, 62.5 mM Tris [pH 6.8], 0.002% bromophenol blue), boiled for 5 min, and spun for 2 min at 10,000 g. The samples were analyzed by SDS-PAGE (3% stacking gel, 10% resolving gel). After staining with Coomassie Blue, gels were washed three times with distilled water and prepared for fluorography by soaking the gels in 1.0 M sodium salicylate for 30 min. After drying, gels were exposed to X-Omat AR x-ray film (Eastman Kodak Co., Rochester, NY) with an intensifier screen for up to 8 d. Human VLDL detected by Coomassie Blue or '4C-labeled protein molecular weight markers (Amersham Corp.) were used as standards. The autoradiographs were quantitated by scanning densitometry as described above. Essentially the same results were obtained when we cut the bands from the gel identified by fluorography and analyzed them by scintillation counting. For this purpose, the gel pieces were treated with tissue homogenizer TS-1 (Research Products International, Mount Prospect, IL) for 2 h at 50°C before scintillation counting.
Miscellaneous. Tumor necrosis factor a was measured as described (33) . Statistical significance was calculated using the two-tailed Student's t test. Data in text is given as mean±standard deviation.
Results Apo E accumulation in the supernatant in the absence or presence of IFN. Our laboratory and others have shown that human monocytic THP-1 cells can be differentiated into macrophage-like cells by incubation with PMA (25, 26) . During PMA-induced differentiation, a dramatic increase in both the level of apo E mRNA and apo E protein can be observed in these cells (7, 26) . Therefore, in initial experiments, THP-1 cells were incubated for 6 d with 10-7 M PMA in the absence or presence of 100 U/ml ofIFN and the accumulation ofapo E in the supernatant was quantitated by immunoassay. This dose of IFN is used widely to study the effects of this lymphokine on monocytic cells including THP-1 cells (34, 35) . Treatment with IFN dramatically decreased the concentration of apo E in the supernatant at day 6 from 268±21 to 65±10 ng/,ig DNA (P < 0.001, n = 3) (Miya, T., and L. K. Curtiss, unpublished observations). In the supernatant ofdividing THP-I cells (i.e., cells without PMA), < 3 ng ofapo E per gg DNA was detected and this was not modulated by the addition of IFN (data not shown). (Fig. 1 A) with PMA±IFN and supernatants were analyzed for the presence ofapo E by Western blot analysis. On days 2, 3, and 4, PMA treatment induced a continuous increase of apo E in the supernatant that was significantly inhibited by the simultaneous exposure to IFN. Fig. 1 B shows a more dramatic inhibitory effect of IFN in a separate experiment in which the accumulation of apo E was analyzed after treatment for 6 d. To detect only monocyte/macrophage-derived apo E and to exclude any effects that might be deri ed from serum-associated lipoproteins, we used a serum-free culture system (1% Nutridoma). As demonstrated earlier (26), THP-1 cells require -1-2 d to adjust to serum-free 1% Nutridoma conditions and this can explain the delayed detection of apo E.
To document specificity ofthe apo E response to IFN, cells were examined for secretion of TNF. It has been established that IFN enhances the secretion of TNF in macrophages (20, 27) . Cells were incubated with PMA± 100 U/ml ofIFN for 4 d and the production of TNF was analyzed. In untreated cells, the concentration of TNF in the supernatant was < 0.09 ng/ 106 cells. After 4 d of incubation with PMA, the TNF concen-A tration had increased to 0.16±0.02 ng/ 106 cells which was further enhanced to 1.18±0.3 ng/ 106 cells by IFN (n = 3). Further support for specificity was obtained from our observation that, in contrast to the results obtained with IFN, incubation with macrophage colony-stimulating factor (M-CSF) or GM-CSF, two other potent cytokines known to modulate monocytic cell function (36) , had no significant effect on apo E production as determined by immunoassay or Western blot analysis either in PMA-treated or in dividing THP-1 cells (Miya, T., and L. K. Curtiss, unpublished observations).
Effect ofIFN on the steady-state levels ofapo E mRNA. To examine if treatment with IFN had an effect on PMA-induced levels ofapo E mRNA, cells were incubated for up to 6 d±IFN. Treatment with PMA induced a dramatic and sustained increase in the steady-state levels of apo E mRNA over a period of 6 d (Fig. 2) . The presence of IFN did not change the apo E mRNA levels during the 6 d ofincubation. This was in contrast to the observed inhibition of apo E accumulation in the supernatant by IFN (Fig. 1) . No apo E mRNA was detected in these studies in dividing THP-l cells or in cells treated with IFN in the absence of PMA over a period of 6 d (data not shown).
Effect ofIFN dose on the accumulation ofintracellular and extracellular apo E. The decreased accumulation of apo E in the supernatant in the presence of IFN without a concomitant change in the levels ofapo E mRNA suggested control by translational and/or posttranslational regulatory mechanisms. To further investigate the level of regulation, we studied the effect of IFN on intracellular as well as extracellular apo E accumulation (Fig. 3) . THP-1 cells were incubated with PMA±IFN (10 or 100 U/ml) for 4 lular apo E accumulation was inhibited by 58±6% at 10 U/ml of IFN and more dramatically inhibited by 89±8% at 100 U/ ml (n = 3). Several molecular weight species of apo E were observed in these blots consistent with previous studies (4, 37 (Fig. 4) . The effect of IFN added after differentiation appeared to be less dramatic than that observed when this lymphokine was added simultaneously with PMA. Furthermore, no difference in intracellular apo E accumulation was detected when differentiated cells were incubated with IFN, even at the higher concentrations. A similar result was observed when differentiated THP-1 cells were treated with IFN for 1 d (data not shown). Incubation ofdifferentiated cells with IFN for 6 h showed only a small inhibition of apo E production (15±2% inhibition at 100 U/ml, n = 2).
Degradation and uptake of extracellular apo E is not increased by IFN. The decreased accumulation of extracellular apo E in the presence of IFN could be due to either increased degradation in the supernatant or increased cellular uptake. To address both alternatives, labeled apo E-enriched culture supernatant (i.e., chase-supernatant from cells incubated with PMA for 4 d, labeled with [35S] methionine for 6 h and chased for 2 h) was added to nonlabeled cells that had been treated with PMA± 100 U/ml ofIFN for 4 d. The supernatant and cell lysate were harvested over 4 h. We detected a similar decrease ofapo E in the chase-supernatant whether it was added to nontreated or IFN-treated cells (Fig. 5 ). In addition, we detected a very low level of extracellular apo E uptake which increased to 3±1% in the absence and 4± 1% in the presence of IFN after 4 h (n = 3). Similar results were obtained when we used labeled apo E-enriched culture supernatant from IFN-treated cells (data not shown).
Uptake ofsecreted apo E also was addressed by an independent experimental approach. Macrophages have high affinity sites that can bind and internalize apo E-containing lipoproteins (38, 39) . This high-affinity uptake in macrophages is absolutely dependent on calcium ions. Therefore, cells were chased with medium containing EGTA at a concentration sufficient to chelate total calcium and magnesium ions in the medium. Furthermore, cells were chased in the presence ofcalcium-and magnesium-free Hanks' balanced salt solution. IFN inhibited the extracellular accumulation of apo E in the presence and absence of calcium by -70% (Table I) . Our data demonstrated that IFN did not increase degradation or uptake of extracellular apo E under our experimental conditions. These results indicated that the decreased accumulation ofextracellular apo E appeared to be mediated by intracellular mechanisms.
Pulse-chase analysis of intracellular and extracellular apo E. Pulse-chase experiments were performed to determine the fate ofthe newly synthesized apo E and to analyze in detail how IFN inhibited the accumulation of apo E in the supernatant. After 4 d with PMA± 100 U/ml of IFN, the cells were pulse-labeled for 2 h with [35S] methionine and chased with cold methionine. We observed a continuous decrease in intracellular apo E in the absence and presence of IFN over the 5-h chase period (Fig. 6 ). In the presence of IFN, the accumulation of apo E in the supernatant was significantly inhibited compared to the control.
Quantitative data from three independent experiments is shown in Table II. In the absence of IFN, the majority ofapo E lost from the intracellular pool during the chase period was recovered in the supernatant. In contrast, in the presence of IFN, the recovery of apo E in the supernatant was significantly reduced despite an accelerated decrease in intracellular levels of apo E. Therefore, our results indicated that IFN increased intracellular apo E degradation. This effect was even more significant because of the apparent reduced secretion efficiency, and appeared to account for the dramatically increased loss of total apo E during the chase period (Table II) .
In the same experiments as described in Table II , we compared the fate of intracellular methionine-labeled total protein with that of intracellular apo E during the chase period in IFNtreated cells. The recovery of intracellular apo E was significantly lower than the recovery of total intracellular protein during the chase period (Table III) icant difference in the recovery of extracellular apo E or total protein was observed. This indicated that IFN specifically increased the intracellular degradation of apo E. Effect of IFN on monocyte-derived macrophages. Finally, we investigated ifthe inhibitory effect of IFN on apo E production also could be observed in human monocyte-derived macrophages. The experiments were performed under similar conditions used for THP-I cells. Adherent peripheral blood monocytes were incubated with 10-8 M PMA±IFN (10 or 100 U/ml) for 2 d (Fig. 7) . At this time, the cells were labeled with [35S]methionine for 6 h and apo E was analyzed in cell lysate and supernatant samples. Incubation with IFN did not change the accumulation of intracellular apo E. However, similar to the results obtained using THP-1 cells, the extracellular apo E accumulation was inhibited by IFN (70±8% by 100 U/ml, n = 3). These data suggested that a similar posttranslational effect ofIFN on apo E production also existed in cultured human monocyte-derived macrophages. 
Discussion
Interactions among lymphocytes and macrophages lie at the center ofthe immune response (40) . This "cross talk" between hematopoietic cells is coordinated by a regulatory network of cytokines and other inflammatory molecules. Our laboratory has demonstrated that apo E isolated from human monocytederived macrophage cultures, synovial fluid and plasma can function as an immunoregulatory monokine-like molecule (15) (16) (17) (18) . Both intact apo E and multimers of a synthetic peptide representing amino acid residues 141-155 of apo E are potent inhibitors of mitogen-and antigen-driven lymphocyte proliferation ( 19) . The present study establishes a mechanism by which the target lymphocyte itself can respond to this "apo E challenge." We show that IFN, a lymphokine produced primarily by activated T cells or large granular lymphocytes (20, 21 ) , can inhibit apo E production in human macrophages.
The accumulation of apo E in the supernatant of cultured THP-1 cells was significantly reduced by IFN when it was present during differentiation or when added to differentiated cells. Treatment with this lymphokine did not change the steadystate levels of apo E mRNA. Furthermore, in the presence of IFN no increased degradation or increased uptake of secreted apo E was observed. Pulse-chase experiments performed in the absence of IFN indicated that the loss of intracellular apo E during the chase period was primarily due to secretion. This recovery ofapo E in the supernatant was significantly inhibited by IFN. In addition, the decrease in intracellular apo E during the chase period was accelerated in IFN-treated cells versus nontreated cells. These data suggested two alternative hypotheses. Either IFN specifically inhibited the secretion ofapo E that favored intracellular degradation, or IFN increased the intra-+ IFN The experiment from Fig. 6 and from two additional experiments were analyzed. The amount of intracellular labeled apo E as determined by scintillation counting present at the beginning of the chase period (0 h) was defined as 100% and the data were calculated as a percentage of this value. Data for recovery were expressed as mean±SD (n = 3). presence of IFN could account for the observed slight inhibition of intracellular accumulation of apo E when this lymphokine was present during differentiation (Fig. 3) . However, at this time we cannot exclude an additional minor translational effect of IFN on apo E synthesis. Further studies are necessary to identify the exact intracellular mechanisms by which IFN exerts its inhibitory effect on apo E production. Intracellular degradation in hepatic cells has been demonstrated to be an important regulatory mechanism controlling the level of secretion of apo B (42) . Insulin and LDL inhibit secretion of apo B and increase intracellular degradation (43, 44) . Oleate, on the other hand, stimulates the secretion of apo B-containing lipoproteins by inhibiting early intracellular degradation (45) . A similar mechanism has been suggested for the HDL-induced apo E production in J774 cells ( 14) . Intracellular degradation also appears to play a regulatory role in the secretion of apo E by Hep G2 cells (46) . Recent reports have described the inhibitory effects of IFN on the production of macrophage lipoprotein lipase (LPL)'
and scavenger receptor (ScR) (47, 48) , which, like apo E, have been identified in atheroma (49) (50) (51) . Activated T cells, the main producers of IFN, are a prominent cell type in atherosclerotic lesions (52) . At particular stages of plaque development, IFN expression may predominate and reduce the expression of apo E, LPL, and ScR. This could protect the lymphocyte from the immunosuppressive effects of macrophage apo E and limit foam cell formation (47, 48) . Inhibition of the production of apo E, LPL, and ScR by the same agonist, IFN, suggests a common theme and may be part of in vivo mechanisms that prevent plaque progression. Defective production ofIFN is associated with immunodeficiency conditions (53) and chronic disease states (21, 54 terestingly, we identified a high level of immunosuppressive apo E in fetal cord blood (55) , which could derive at least in part from the physiologic defect in IFN production that has been identified in human neonates (56) . Therefore, we speculate that the expression of macrophage apo E in vivo can be modulated by immunoregulatory substances like IFN and possibly in acute inflammatory situations also by inflammatory molecules such as bacterial lipopolysaccharide (9) . A loss of this control under conditions described above, could lead to an increased production of "lymphocyte-suppressive" apo E which could contribute to an immunodeficient condition.
Our study has demonstrated that the lymphokine IFN inhibited apo E production in human macrophages by posttranslational mechanisms, which included increased intracellular degradation and/or inhibition of secretion. Inhibition of macrophage-apo E production by IFN represents a previously uncharacterized interaction between T lymphocytes and macrophages and may serve as an example ofthe growing amount of evidence to support a relationship between lipid metabolism and immune cell function.
